Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

We have previously demonstrated a 33% response rate in patients with primitive neurectodermal tumours after the direct injection of 131I-monoclonal antibodies (MAbs) into the cerebrospinal fluid (CSF). Dose-limiting toxicity is myelosuppression due to the passage of the radioimmunoconjugate from the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kemshead, J. T., Hopkins, K., Pizer, B., Papanastassiou, V., Coakham, H., Bullimore, J., Chandler, C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 1998
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2150406/
https://ncbi.nlm.nih.gov/pubmed/9649153
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi